Vascular Biogenics (STU:0VB) Cyclically Adjusted FCF per Share: €0.00 (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vascular Biogenics Cyclically Adjusted FCF per Share?

Vascular Biogenics STU:0VB 10 Cyclically Adjusted FCF per Share is €0.00 as of Jun. 2023. GuruFocus rates STU:0VB with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted FCF per Share is a main component used to calculate Cyclically Adjusted Price-to-FCF. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Vascular Biogenics's adjusted free cash flow per share for the three months ended in Jun. 2023 was €-0.028. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-24), Vascular Biogenics's current stock price is €0.00. Vascular Biogenics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2023 was €0.00. Vascular Biogenics's Cyclically Adjusted Price-to-FCF of today is .


Vascular Biogenics  (STU:0VB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Vascular Biogenics Cyclically Adjusted FCF per Share Related Terms


Vascular Biogenics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Vascular Biogenics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vascular Biogenics Cyclically Adjusted FCF per Share Chart

Vascular Biogenics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vascular Biogenics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:0VB vs MBIO, GNPX, LEXX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Vascular Biogenics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vascular Biogenics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vascular Biogenics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vascular Biogenics's Cyclically Adjusted Price-to-FCF falls into.



Vascular Biogenics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vascular Biogenics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-0.028/305.1090*305.1090
=-0.028

Current CPI (Jun. 2023) = 305.1090.

Vascular Biogenics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201309 0.000 234.149 0.000
201312 -0.224 233.049 -0.293
201403 -0.198 236.293 -0.256
201406 -0.115 238.343 -0.147
201409 -2.737 238.031 -3.508
201412 -0.102 234.812 -0.133
201503 -0.102 236.119 -0.132
201506 -0.135 238.638 -0.173
201509 -0.173 237.945 -0.222
201512 -0.180 236.525 -0.232
201603 -0.161 238.132 -0.206
201606 -0.133 241.018 -0.168
201609 -0.094 241.428 -0.119
201612 -0.124 241.432 -0.157
201703 -0.199 243.801 -0.249
201706 -0.208 244.955 -0.259
201709 -0.192 246.819 -0.237
201712 0.235 246.524 0.291
201803 -0.135 249.554 -0.165
201806 -0.136 251.989 -0.165
201809 -0.122 252.439 -0.147
201812 -0.075 251.233 -0.091
201903 -0.074 254.202 -0.089
201906 -0.057 256.143 -0.068
201909 -0.096 256.759 -0.114
201912 -0.102 256.974 -0.121
202003 -0.149 258.115 -0.176
202006 -0.142 257.797 -0.168
202009 -0.067 260.280 -0.079
202012 -0.118 260.474 -0.138
202103 -0.100 264.877 -0.115
202106 -0.069 271.696 -0.077
202109 -0.090 274.310 -0.100
202112 -0.085 278.802 -0.093
202203 -0.103 287.504 -0.109
202206 -0.124 296.311 -0.128
202209 -0.088 296.808 -0.090
202212 -0.082 296.797 -0.084
202303 -0.020 301.836 -0.020
202306 -0.028 305.109 -0.028

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.00 mean?
Vascular Biogenics (STU:0VB) has a Cyclically Adjusted FCF per Share of €0.00 as of Jun. 2023. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vascular Biogenics and its competitors.
Is Vascular Biogenics' Cyclically Adjusted FCF per Share too high?
Vascular Biogenics' current Cyclically Adjusted FCF per Share is €0.00. Overall, Vascular Biogenics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Vascular Biogenics' Cyclically Adjusted FCF per Share compare to MBIO and GNPX?
Vascular Biogenics' Cyclically Adjusted FCF per Share of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vascular Biogenics and its competitors. Vascular Biogenics's current Cyclically Adjusted FCF per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vascular Biogenics stock overvalued right now?
Vascular Biogenics (STU:0VB) has a current Cyclically Adjusted FCF per Share of €0.00. The current Cyclically Adjusted FCF per Share is €0.00. Vascular Biogenics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Vascular Biogenics (STU:0VB), the current Cyclically Adjusted FCF per Share is €0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vascular Biogenics Business Description

Address 8 HaSatat Street, Modi’in, ISR, 7178106
Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.